The combination of AdC68-mFAP with the AdC68-gDMelapoly vaccine, which targeted melanoma antigens, further amplified these effects, as evidenced by a reduction in tumor mass, an increase in the number and functional activity of tumor-infiltrating CD8+ T-cells [115]. This evidence concerns the gene CD8A and neoplasm.